The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis
Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity · 01.02.2025 · 30 (1)
DOI: 10.1007/s40519-025-01720-9 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, online erschienen am 01.02.2025. Verfasst von Hanieh Radkhah und 8 weiteren Autor:innen. Beteiligte Einrichtung: Sina Hospital, Department of Internal Medicine, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Feeding and Eating Disorders, Glucagon-Like Peptide-1 Receptor Agonists, Binge-Eating Disorder. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Glucagon-like peptide-1 (GLP-1) receptor agonists have shown potential in managing eating disorders (EDs). Recent studies highlight their effects on pathophysiological pathways, indicating their therapeutic promise, particularly for binge eating disorder (BED). This systematic review evaluates the therapeutic effects of GLP-1 agonists on BED, focusing on weight management and eating behaviors.
Methods
A systematic search of PubMed, Scopus, Web of Science, and the Cochrane Library, along with manual searches, identified studies assessing GLP-1 agonists in BED patients up to November 8, 2024. Observational studies and clinical trials meeting inclusion criteria were analyzed.
Results
Five studies (182 participants) were included. Patients receiving GLP-1 agonists experienced greater weight loss (− 3.81 kg; 95% CI − 5.14 to − 2.49; p < 0.01, I 2 : 59.88%) compared to controls. GLP-1 agonists significantly reduced BMI (− 1.48 kg/m 2 ) and waist circumference (− 3.14 cm). Binge Eating Scale (BES) scores improved significantly (− 8.14 points; 95% CI − 13.13 to − 3.15; p < 0.01), though heterogeneity was noted.
Conclusions
This review underscores the potential role of GLP-1 agonists in BED management. However, given the limited data, especially concerning EDs other than BED and the long-term effects of these medications, further comprehensive clinical trials are recommended to evaluate the impact of various GLP-1 agonists on different EDs across diverse demographic groups. Level of evidence Level I, randomized controlled trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sina Hospital, Department of Internal Medicine, Tehran University of Medical Sciences, Tehran, Iran.
- School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
- Tehran University of Medical Sciences, Tehran, Iran.
- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
- Cellular and Molecular Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Students' Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran.
Zitieren
APA
Radkhah, H., Rahimipour Anaraki, S., Parhizkar Roudsari, P., Arabzadeh Bahri, R., Zooravar, D., Asgarian, S., Hosseini Dolama, R., Alirezaei, A., & Khalooeifard, R. (2025). The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis. Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, 30(1). https://doi.org/10.1007/s40519-025-01720-9
Vancouver
Radkhah H, Rahimipour Anaraki S, Parhizkar Roudsari P, Arabzadeh Bahri R, Zooravar D, Asgarian S, et al. The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis. Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity. 2025;30(1). doi:10.1007/s40519-025-01720-9
BibTeX
@article{Radkhah2025,
author = {Radkhah, Hanieh and Rahimipour Anaraki, Shiva and Parhizkar Roudsari, Peyvand and Arabzadeh Bahri, Razman and Zooravar, Diar and Asgarian, Sara and Hosseini Dolama, Reza and Alirezaei, Ali and Khalooeifard, Razieh},
title = {The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis},
journal = {Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity},
year = {2025},
volume = {30},
number = {1},
doi = {10.1007/s40519-025-01720-9}
}
EUVIMED